Tenax Therapeutics (NASDAQ:TENX) Drops 85% as Phase 3 LEVEL Study Fails to Meet Main Endpoints
NEW YORK, Aug. 10, 2026 — Shares of Tenax Therapeutics tumbled around 85% ahead of Monday’s market open after the company reported that its Phase 3 LEVEL trial with oral levosimendan did not achieve its primary endpoint for exercise capacity or its main symptom endpoint.
